Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoît Baron

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding studyXavier Paoletti, Benoît Baron, Patrick Schöffski, et al.
Advanced Drug Delivery Reviews|August 19, 2007
Implications of circadian clocks for the rhythmic delivery of cancer therapeuticsFrancis Lévi, Christian Focan, Abdoulaye Karaboué, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy GroupSylvie Giacchetti, Georg Bjarnason, Carlo Garufi, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
European Journal of Cancer (Oxford, England : 1990)|June 3, 2006
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding studyXavier Paoletti, Benoît Baron, Patrick Schöffski, et al.
Advanced Drug Delivery Reviews|August 19, 2007
Implications of circadian clocks for the rhythmic delivery of cancer therapeuticsFrancis Lévi, Christian Focan, Abdoulaye Karaboué, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy GroupSylvie Giacchetti, Georg Bjarnason, Carlo Garufi, et al.
Pageof 1